secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001213900-25-039184
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma says 2023 financials error resolved in filed 10-K, no amendment needed
--------------------------------------------------------------------------------

- Original 8-K on Apr 15, 2025 flagged 2023 financials for errors, requiring amendment.
- After discussions with auditor Simon & Edward LLP, management determined corrections adequately addressed in the 2024 10-K filed Apr 15, 2025.
- Company will not file the previously planned 2023 Amendment; prior non-reliance is effectively rescinded.
- Auditor Simon & Edward LLP concurred with management's conclusion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025039184/0001213900-25-039184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025039184/ea024046901-8ka_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-039184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer